On Friday, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) opened higher 15.75% from the last session, before settling in for the closing price of $0.13. Price fluctuations for ADAP have ranged from $0.04 to $1.01 over the past 52 weeks.
During the last 5-year period, the sales growth of Healthcare Sector giant was 26.53%. Company’s average yearly earnings per share was noted -60.00% at the time writing. With a float of $255.41 million, this company’s outstanding shares have now reached $265.05 million.
Adaptimmune Therapeutics Plc ADR (ADAP) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Adaptimmune Therapeutics Plc ADR is 3.64%, while institutional ownership is 27.58%. The most recent insider transaction that took place on Sep 02 ’25, was worth 950. In this transaction Chief Financial Officer of this company sold 96,000 shares at a rate of $0.01, taking the stock ownership to the 0 shares. Before that another transaction happened on Sep 02 ’25, when Company’s Chief Financial Officer proposed sale 16,000 for $0.06, making the entire transaction worth $942.
Adaptimmune Therapeutics Plc ADR (ADAP) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.01 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.18) by 0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -60.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.87% during the next five years compared to 26.53% growth over the previous five years of trading.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Trading Performance Indicators
Check out the current performance indicators for Adaptimmune Therapeutics Plc ADR (ADAP). In the past quarter, the stock posted a quick ratio of 1.29. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.19 in one year’s time.
Technical Analysis of Adaptimmune Therapeutics Plc ADR (ADAP)
Looking closely at Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP), its last 5-days average volume was 88.19 million, which is a jump from its year-to-date volume of 26.98 million. As of the previous 9 days, the stock’s Stochastic %D was 45.89%.
During the past 100 days, Adaptimmune Therapeutics Plc ADR’s (ADAP) raw stochastic average was set at 33.61%, which indicates a significant decrease from 57.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0308 in the past 14 days, which was higher than the 0.0195 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.1075, while its 200-day Moving Average is $0.3282. However, in the short run, Adaptimmune Therapeutics Plc ADR’s stock first resistance to watch stands at $0.1617. Second resistance stands at $0.1763. The third major resistance level sits at $0.1907. If the price goes on to break the first support level at $0.1327, it is likely to go to the next support level at $0.1183. Now, if the price goes above the second support level, the third support stands at $0.1037.
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Key Stats
There are currently 265,052K shares outstanding in the company with a market cap of 38.96 million. Presently, the company’s annual sales total 178,030 K according to its annual income of -70,810 K. Last quarter, the company’s sales amounted to 13,680 K and its income totaled -30,340 K.
